ENTROVAS-97/103 Tablet

About ENTROVAS-97/103 Tablet

ENTROVAS-97/103 is a tablet combining sacubitril and valsartan, used in heart failure. It contains a neprilysin inhibitor and an angiotensin receptor blocker, and is available as a 97 mg + 103 mg tablet.

There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.

What is ENTROVAS-97/103 Tablet?

ENTROVAS-97/103 is a tablet medicine that combines two active substances: sacubitril and valsartan. Sacubitril belongs to a group called neprilysin inhibitors, and valsartan is an angiotensin receptor blocker. Together they are used in the treatment of heart failure. The tablet is made by Renata PLC. It is available in a strength of 97 mg + 103 mg. Heart failure is a long-term condition, and treatment should be managed by a doctor who can decide whether this medicine is suitable.

Uses of ENTROVAS-97/103

ENTROVAS-97/103 is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure and reduced ejection fraction. It is also used for symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. Your doctor will assess your condition and decide if this medicine is appropriate for you.

How to use ENTROVAS-97/103

ENTROVAS-97/103 is taken by mouth as a tablet. The doctor decides the dose and how often you take it, including any change in dose over time. Do not adjust the dose yourself. Swallow the tablet as directed by your doctor. If you miss a dose, ask your doctor or pharmacist what to do. Keep all appointments so your doctor can check your progress and adjust treatment if needed.

Side effects of ENTROVAS-97/103

Like all medicines, ENTROVAS-97/103 can cause side effects. The most common ones include angioedema, low blood pressure, impaired kidney function, high potassium levels, cough, and dizziness. Some side effects can be serious. Tell your doctor promptly if you notice swelling, difficulty breathing, or a big drop in blood pressure. Your doctor may monitor your kidney function and potassium levels during treatment.

Safety and precautions

ENTROVAS-97/103 must not be used by anyone with a known allergy to any ingredient, or with a history of angioedema linked to an ACE inhibitor or ARB. It should not be taken with ACE inhibitors, or with aliskiren in people with diabetes. It is not recommended in severe liver impairment. Tell your doctor if you are pregnant, planning pregnancy, or breastfeeding. Also inform your doctor about kidney problems, high potassium, or other medicines you take, so they can decide if it is safe for you.

Frequently asked questions

What is ENTROVAS-97/103 used for and what kind of medicine is it?

ENTROVAS-97/103 is a combination tablet of sacubitril and valsartan. It is used to treat heart failure in adults and in children aged one year and older. Sacubitril is a neprilysin inhibitor and valsartan is an angiotensin receptor blocker. Your doctor will decide if it is right for you.

Who should avoid ENTROVAS-97/103 or ask the doctor first?

Do not take it if you have had angioedema with an ACE inhibitor or ARB, or if you are allergic to any ingredient. Avoid it with ACE inhibitors or with aliskiren if you have diabetes. Ask your doctor first if you are pregnant, breastfeeding, have kidney or liver problems, or take other medicines.

How should ENTROVAS-97/103 be taken?

Take the tablet by mouth as instructed by your doctor. The doctor decides the dose and how often you take it, and may change the dose over time. Do not change the dose yourself. If you miss a dose, ask your doctor or pharmacist for advice. Keep your appointments for monitoring.

What should I tell my doctor before starting ENTROVAS-97/103?

Tell your doctor about any allergies, especially swelling problems, and all other medicines you take, including ACE inhibitors, potassium-sparing diuretics, NSAIDs, or lithium. Mention if you have kidney or liver problems, high potassium, or if you are pregnant or breastfeeding. Your doctor will decide if this medicine is suitable.

Indications

This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • ... Read more
This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.

Pharmacology

This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.

Dosage & Administration

Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.

Reduce the starting dose to 24/26 mg twice daily for:
  • Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
  • Patients with severe renal impairment.
  • Patients with moderate hepatic impairment.
Pediatric Heart Failure: Refer to Table 1 for the recommended dose for pediatric patients aged one year and older. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.

Recommended Dose Titration-

Pediatric Patients Less than 40 kg:
  • Starting: 1.6 mg/kg
  • Second: 2.3 mg/kg
  • Final: 3.1 mg/kg
Pediatric Patients At least 40 kg, less than 50 kg:
  • Starting: 24/26 mg
  • Second: 49/51 mg
  • Final: 49/51 mg
Pediatric Patients At least 50 kg:
  • Starting: 49/51 mg
  • Second: 72/78 mg
  • Final: 97/103 mg

Interaction

Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.

Contraindications

This combination is contraindicated:
  • In patients with hypersensitivity to any component
  • In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy 
  • With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor 
  • With concomitant use of aliskiren in patients with diabetes

Side Effects

The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.

Pregnancy & Lactation

Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.

Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
 
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.

Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.

Precautions & Warnings

This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.

This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.

Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.

Overdose Effects

Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.

Storage Conditions

Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.

Alternative brands of Sacubitril + Valsartan

Other brands with the same generic name, cheapest first.

See all 25 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.